Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rank in Stocks #25179
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Share Price
$1.95
Last synced: 2022-07-29
Market Cap
$52.48M
Change (1 day)
2.63%
Change (1 year)
0.00%
Country
US
Trade Cortexyme, Inc. (CRTX)

Category

Stock price history for Cortexyme, Inc. (CRTX)
Highest end of day price: $2.18 on 2022-07-01

Lowest end of day price: $26.37 on 2019-05-01
Stock price history of Cortexyme, Inc. from 2019 to 2026
Annual Stock Price Performance
Year Performance
2022 -82.87%
2021 -62.60%
2020 -23.16%
2019 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$539.14 35.65%
US
$1.04K 56.21%
NL
$118.70 -18.24%
AU
$761.87 8.65%
CH
$130.43 397.46%
US